Karim El-Shakankery
Impact in
-
- PARP inhibition in cancer therapy
- COVID-19 and healthcare impacts
- Cancer Cells and Metastasis
- Pancreatic and Hepatic Oncology Research
-
- Ovarian cancer diagnosis and treatment
Papers in
- Oncology 9
- Cancer Immunotherapy and Biomarkers 3
- PARP inhibition in cancer therapy 2
- Lung Cancer Research Studies 2
- COVID-19 and healthcare impacts 2
- Co-authors
- Rowan Miller (5 shared papers)Jung‐Yun Lee (1 shared paper)Francesco Di Maggio (1 shared paper)Shanthini Mary Crusz (3 shared papers)Jonathan A. Ledermann (2 shared papers)Ellen Nelissen (1 shared paper)Ewelina Rogozińska (1 shared paper)Jo Morrison (1 shared paper)
- Journals
- Frontiers in Oncology (2 papers)Journal of Clinical Oncology (1 paper)Cochrane Database of Systematic Reviews (1 paper)Women s Health (1 paper)Journal of Gynecologic Oncology (1 paper)
- Partner nations
- United KingdomAustraliaSouth Korea
In The Last Decade
Karim El-Shakankery
15 papers receiving 132 citations
Peers
Comparison fields: 5 of 42
- Oncology 69
- Reproductive Medicine 19
- Cancer Research 13
- Obstetrics and Gynecology 6
- Biomaterials 8
Countries citing papers authored by Karim El-Shakankery
This map shows the geographic impact of Karim El-Shakankery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karim El-Shakankery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karim El-Shakankery more than expected).
Fields of papers citing papers by Karim El-Shakankery
This network shows the impact of papers produced by Karim El-Shakankery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karim El-Shakankery. The network helps show where Karim El-Shakankery may publish in the future.
Co-authors
The 25 scholars most cited alongside Karim El-Shakankery, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 33 | |
| 2 | 2020 | 22 | |
| 3 | 2020 | 21 | |
| 4 | 2022 | 16 | |
| 5 | 2023 | 14 | |
| 6 | 2020 | 10 | |
| 7 | 2020 | 6 | |
| 8 | 2021 | 3 | |
| 9 | 2023 | 2 | |
| 10 | ROX Index to Guide Management of COVID-19 Pneumonia | 2021 | 1 |
| 11 | 2024 | 1 | |
| 12 | 2020 | 1 | |
| 13 | 2017 | 1 | |
| 14 | 2016 | 1 | |
| 15 | 2024 | 1 | |
| 16 | 2024 | 0 | |
| 17 | 2024 | 0 |
About Karim El-Shakankery
Karim El-Shakankery is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Infectious Diseases, Molecular Biology and Neurology, having authored 17 papers that have together received 133 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (3 papers), DNA Repair Mechanisms (2 papers), Ovarian cancer diagnosis and treatment (2 papers), PARP inhibition in cancer therapy (2 papers), Lung Cancer Research Studies (2 papers), COVID-19 and healthcare impacts (2 papers), Simulation-Based Education in Healthcare (1 paper) and Surgical Simulation and Training (1 paper). The work is most often cited by research in Oncology (69 citations), Reproductive Medicine (19 citations), Cancer Research (13 citations), Obstetrics and Gynecology (6 citations) and Biomaterials (8 citations). Karim El-Shakankery has collaborated with scholars based in United Kingdom, Australia and South Korea. Frequent co-authors include Rowan Miller, Jung‐Yun Lee, Francesco Di Maggio, Shanthini Mary Crusz, Jonathan A. Ledermann, Ellen Nelissen, Ewelina Rogozińska, Jo Morrison, Sherine Thomas and Nina Goldman. Their work appears in journals such as Frontiers in Oncology, Journal of Clinical Oncology, Cochrane Database of Systematic Reviews, Women s Health and Journal of Gynecologic Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.